Literature DB >> 16570021

Characterization of anti-Gal antibody-producing cells of baboons and humans.

Yuanxin Xu1, Yong-Guang Yang, Hideki Ohdan, David Ryan, David Harper, Cecelia Wu, Huw S Kruger-Grey, Aron D Thall, Michel Awwad, Megan Sykes.   

Abstract

BACKGROUND: Anti-Gal antibodies cause hyperacute and delayed xenograft rejection in pig-to-primate transplantation. The cell populations producing anti-Gal and other natural antibodies in primates are unknown.
METHODS: Cells from different lymphoid compartments of naïve or sensitized baboons were examined for anti-Gal and total Ig production by ELISPOT. B and plasma cells from humans and baboons were purified by FACS sorting and characterized for anti-Gal and total Ig production and cytology.
RESULTS: In naïve baboons, the spleen was the major source of anti-Gal IgM-secreting cells. Two months after sensitization with porcine tissues, high frequencies of anti-Gal IgM- and IgG-secreting cells were detected in the spleen, lymph nodes, and bone marrow. Six months after antigen exposure, anti-Gal IgM- and IgG-secreting cells were preferentially localized in the bone marrow. Cells from human spleen, bone marrow, and blood were also analyzed and anti-Gal IgM-secreting cells were detected mainly in the spleen. Sorting of baboon and human cells showed that anti-Gal IgM-secreting cells were mainly splenic B cells (CD20+, CD138-, and Ig+). Although low in percentage, sorted CD20-CD138+ plasma cells in spleen and bone marrow secreted large quantities of anti-Gal IgM. Most anti-Gal IgG-secreting cells were plasma cells (CD138+) at both early (Ig+) and late (Ig-) stages of differentiation.
CONCLUSIONS: Similar to Gal knockout mice, natural anti-Gal IgM antibodies in primates are produced mainly by splenic B cells. After antigen exposure, anti-Gal IgM and IgG were secreted by both B and plasma cells. These results suggest strategies to remove xenoreactive antibody-secreting cells prior to transplantation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16570021     DOI: 10.1097/01.tp.0000203300.87272.a3

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  8 in total

Review 1.  Immunological challenges and therapies in xenotransplantation.

Authors:  Marta Vadori; Emanuele Cozzi
Journal:  Cold Spring Harb Perspect Med       Date:  2014-04-01       Impact factor: 6.915

Review 2.  IXA Honorary Member Lecture, 2017: The long and winding road to tolerance.

Authors:  Megan Sykes
Journal:  Xenotransplantation       Date:  2018-05       Impact factor: 3.907

3.  IgM production by bone marrow plasmablasts contributes to long-term protection against intracellular bacterial infection.

Authors:  Rachael Racine; Maura McLaughlin; Derek D Jones; Susan T Wittmer; Katherine C MacNamara; David L Woodland; Gary M Winslow
Journal:  J Immunol       Date:  2010-12-08       Impact factor: 5.422

Review 4.  Progress in xenotransplantation: overcoming immune barriers.

Authors:  Megan Sykes; David H Sachs
Journal:  Nat Rev Nephrol       Date:  2022-10-05       Impact factor: 42.439

5.  Identification of an anti-idiotypic antibody that defines a B-cell subset(s) producing xenoantibodies in primates.

Authors:  Jacqueline Fischer-Lougheed; Clare Gregory; Zena White; Irina Shulkin; Mirja Gunthart; Mary Kearns-Jonker
Journal:  Immunology       Date:  2007-10-03       Impact factor: 7.397

Review 6.  Xenotransplantation: immunological hurdles and progress toward tolerance.

Authors:  Adam Griesemer; Kazuhiko Yamada; Megan Sykes
Journal:  Immunol Rev       Date:  2014-03       Impact factor: 12.988

7.  Virus recognition by specific natural antibodies and complement results in MHC I cross-presentation.

Authors:  Antoine Dürrbach; Emma Baple; Andrew F Preece; Bernard Charpentier; Kenth Gustafsson
Journal:  Eur J Immunol       Date:  2007-05       Impact factor: 5.532

Review 8.  Current status of xenotransplantation research and the strategies for preventing xenograft rejection.

Authors:  Qiao Zhou; Ting Li; Kaiwen Wang; Qi Zhang; Zhuowen Geng; Shaoping Deng; Chunming Cheng; Yi Wang
Journal:  Front Immunol       Date:  2022-07-28       Impact factor: 8.786

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.